Entertainment and intellectual property
Pharmaceutical royalties
A pharmaceutical royalty starts with a licence: a university or a biotech hands a compound to a company that can develop and sell it, in exchange for milestones and a percentage of net sales. Those streams are then bought and sold, which is how a laboratory discovery becomes a traded income asset.
Start here if the word royalty is all you know: somebody uses something you own, and a slice of what they earn from that use is sent to you. Everything on this page is a description of who counts the uses, who writes the cheque, when it arrives and what makes it shrink. What would mislead: assuming one royalty is like another. The rules below apply to this type only, and the money can arrive months after the use that earned it.
How the payment is calculated
The running royalty is a percentage of net sales of the licensed product in each country, and net sales is defined at length: gross invoiced sales less returns, wholesaler fees, chargebacks, government and payer rebates, and discounts. In markets with heavy rebating the gap between what a patient's insurer is billed and what counts as net sales is very large, and it sits entirely inside that definition.
Rates are commonly tiered, stepping up as annual sales pass defined thresholds, and can step down when a third-party licence must also be paid, when a patent lapses in a given country, or when generic competition reaches a defined share.
Milestones are separate: fixed payments on defined events such as trial completion, regulatory filing, approval, or first commercial sale in a major market. They are conditional, not scheduled, and a programme that stops paying milestones has usually stopped.
The royalty term is defined per country and per product, typically as the later of patent expiry, regulatory exclusivity, or a fixed number of years from first commercial sale in that country. When the term ends, the payment ends.
How often it arrives
Quarterly, in arrears, on a royalty report from the marketer. Reporting lags a quarter or more behind the sales it describes, and payments are made in the currency and on the terms the licence specifies.
What erodes it
Every royalty shrinks. What differs is the mechanism and the speed.
This is the section that separates a royalty from a bond. Nobody promised you a number: the payment follows how much use there is, and use fades. A song is played less, a patent expires, a well produces less every year it runs. Where this misleads: reading last year's payment as a run rate. The honest question is not what it paid, but how many years of paying are left and at what level.
Loss of exclusivity
This is the defining risk. When patents and regulatory exclusivity end, generic or biosimilar entry can take most of a product's sales in a short period. It is a cliff on a known date, not a gradual fade.
The net sales definition
Rebates, chargebacks and payer discounts are deducted before the royalty is computed. Policy changes that increase mandatory discounts reduce the royalty without changing a single prescription.
Competition
A better-tolerated or more convenient therapy can displace a product years before its patents expire.
Step-downs and stacking
Contractual step-downs triggered by third-party licences or by competition can cut the rate materially while sales continue.
Development failure
A royalty on an unapproved compound is a claim on an event that may never occur. Trial failure, a regulatory rejection or a safety signal reduces it to nothing.
Counterparty
The payment comes from the marketer. A licence assignment, a restructuring or a dispute over the calculation puts the stream in the hands of a party that may have no relationship with the original inventor.
What diligence looks like
Diligence on a royalty is mostly document work: proving the right exists, proving the seller owns it, and proving the payments you were shown came from it. The easy mistake: a statement showing money arriving. A statement proves that a payment was made, not that the right behind it is unencumbered, correctly registered, or yours after the sale.
- Read the licence agreement, above all the definitions of licensed product, net sales and royalty term.
- Map patent expiry and regulatory exclusivity country by country, including any term extensions and paediatric exclusivity.
- Identify every step-down and step-up trigger and model the rate, not just the sales.
- Assess competitive and pipeline threats to the product's indication.
- Check audit rights, currency terms, set-off rights and anti-assignment clauses.
- Establish who actually pays, and what happens if the product is divested to another company.
- For development-stage streams, read the trial design and the milestone conditions rather than the headline royalty rate.
Tax treatment
Royalty receipts are ordinary income. A university or non-profit licensor has its own regime; an individual inventor's treatment depends on whether inventing is their trade or business.
A sale of the royalty right can be capital in character where all substantial rights transfer, and section 1235 treatment is specific to patents and to qualifying holders.
Buyers of royalty streams are recovering a purchase price against income received, and the mechanics depend on how the acquisition was structured. This is a professional-advice question in every real transaction.
Listed vehicles with exposure to this
A research screen from our database, sorted by ticker, not ranked.
These trade on an exchange, so they solve the hardest problem with a royalty — that there is normally nobody to sell it to. What they add is a wrapper with its own costs, its own management and, in a trust's case, an end date. What would mislead: the yield shown is trailing, meaning it measures the last twelve months of payments against today's price. On a trust holding a pool that cannot be refilled, that figure describes a year that will not come round again.
These are the exchange-listed vehicles in our universe whose exposure overlaps this royalty type, in ticker order. The structure column is our own classification of the wrapper and decides how the rest of the row reads; the yield and dollar figures are trailing twelve-month distributions over the current price, not a forward estimate and not a promise about the next twelve months. The caveat: a listed wrapper around a royalty is a different instrument from the royalty itself — it prices daily, carries the wrapper's own costs and governance, and in a trust's case is winding down by design.
| Ticker | Name | StructureThe wrapper. A finite trust and an operating company behave very differently. | Price | Trailing 12m yieldThe cash paid over the last twelve months, over today's price. A year already gone, not a rate for the year ahead. | Trailing 12m paidWhat one share actually paid over those twelve months, in dollars. | Pays | Market cap | Yrs paying | Last ex-date |
|---|---|---|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | Pharmaceutical royalty company | $62.07 | 1.49% | $0.93 | Quarterly | $27.51B | 6.00 | Aug 14, 2026 |
Prices as of Aug 25, 2026.
A royalty trust is not a company. It is a fixed pool of interests in specific wells, dropped into a trust that is forbidden to buy anything new. The trustee collects what those wells produce, pays the trust's costs, and passes the rest through. Every distribution therefore contains a return of the buyer's own capital as the reserves run down, and the trust ends when the pool is exhausted or falls below a wind-up threshold written into the trust agreement. This is why a trailing yield on a trust overstates the future: the numerator is the last twelve months of a stream that is, by design, finite and declining. A company that owns minerals can buy more acreage and replace what depletes. A trust cannot.
Where interests like this change hands
Royalty Exchange
Music and IP
- What trades there
- Music royalty streams above all — a songwriter's share, a publisher's share, master recording income, sometimes a whole small catalogue. Other IP streams (film, book, patent) appear from time to time.
- How the sale works
- Listed sale. Each offering is published with historical earnings statements attached, then sold by a timed online auction or as a fixed listing; larger catalogues are sometimes handled as a negotiated private sale off the public board.
- Typical buyer
- Individual investors and small funds buying an income stream outright, plus catalogue acquirers using it as deal flow.
SongVest
Music and IP
- What trades there
- Music royalties, sold both as whole streams and as fractional interests in a single song or a small group of songs.
- How the sale works
- Two routes. Fractional interests are offered to the public through a registered or exempt securities offering with its own disclosure document; whole-stream sales are negotiated between seller and buyer.
- Typical buyer
- Retail buyers and fans at the fractional end; catalogue investors at the whole-stream end.
Sedo
Music and IP
- What trades there
- Domain names — outright sale, lease-to-own and parking.
- How the sale works
- Marketplace listing at a fixed price or make-offer, with brokered sales for larger names. Transfer and payment run through the platform's own escrow.
- Typical buyer
- Businesses buying the exact name they want, plus domain investors.
Afternic
Music and IP
- What trades there
- Domain names, sold and leased through a distribution network that surfaces the listing inside registrar search results.
- How the sale works
- Fixed-price 'buy it now' and offer/counter-offer, settled by the platform; instalment and lease-to-own plans hold the name in the platform's control until the last payment clears.
- Typical buyer
- End-user businesses, and investors buying inventory.
These are the visible venues. Most mineral and royalty interests never touch one. They move through a broker or a landman working a specific county, through an unsolicited offer letter mailed to an owner whose name appears in the county deed records, through an operator buying up the royalty under its own wells, and through probate when an estate is settled. County records are the real order book: ownership, leases, assignments and prior sale prices are filed at the courthouse where the land sits. Music is the same story one level up — the marketplaces are the retail end, and most catalogue value trades in privately negotiated deals brokered by specialist advisers. A price you see on a public venue is not a market quote for anything else.
Primary sources
The registers, regulators and collecting bodies that hold the authoritative record.
- US Food and Drug Administration ↗ Approvals, exclusivity listings and the Orange Book
- USPTO ↗ Patent status, term adjustments and extensions
- SEC EDGAR ↗ Licence agreements filed as exhibits by listed licensors and licensees
Where to look
An auction marketplace where music and other intellectual-property royalty streams are sold, with historical payout statements published for each listing.
Listings disclose the payment history the sale price is being bid against
Visit Royalty Exchange ↗An online auction platform for oil and gas mineral rights, royalty interests and working interests, including some state and federal lease offerings.
A working interest carries operating costs and liability; a royalty interest does not
Visit EnergyNet ↗The US organisation designated to collect and distribute digital performance royalties for sound recordings to rights owners and performers.
Covers the recording, which is a separate right from the underlying composition
Visit SoundExchange ↗A performing rights organisation that licenses public performance of musical works and distributes the resulting royalties to songwriters and publishers.
Songwriters affiliate with one performing rights organisation at a time
Visit ASCAP ↗Listed for reference. A row without a Sponsored badge is a plain outbound link and we earn nothing from it.
Frequently asked
Who sells pharmaceutical royalties?
Why does a royalty stream end abruptly?
What does 'net sales' actually mean here?
Can an individual buy a pharmaceutical royalty directly?
Are development-stage royalties comparable to approved ones?
Research only. Nothing on this page is investment, tax or legal advice, and no part of it recommends buying or selling any royalty interest, security or property. Every figure shown in a table comes from our database; everything else describes how these instruments are structured. The documents governing a specific interest override every general statement here.